Eterna Therapeutics Inc
ERNA1.505USD
-0.055-3.53%
Market hours （ET）Quotes delayed by 15 min
78.64MMarket Cap
LossP/E TTM
More Details of Eterna Therapeutics Inc Company
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
Company Info
Ticker SymbolERNA
Company nameErnexa Therapeutics Inc
IPO dateAug 29, 1991
CEOMr. Sanjeev Luther
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 29
Address1035 Cambridge Street
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02141
Phone16177986700
Websitehttps://www.ernexatx.com/
Ticker SymbolERNA
IPO dateAug 29, 1991
CEOMr. Sanjeev Luther
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Feb 24
Currency: USDUpdated: Mon, Feb 24
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
By RegionUSD
Name
Revenue
Proportion
United States
5.48M
94.48%
Canada
320.00K
5.52%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Subscription revenue
4.88M
84.17%
Other revenue
492.00K
8.48%
Hardware revenue
426.00K
7.34%
Shareholding Stats
Updated: Thu, Jul 31
Updated: Thu, Jul 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Shareholders
Shareholders
Proportion
Cherington (Charles)
37.73%
Freebird Partners LP
5.63%
Halpern (John D)
5.30%
Denny George P Iii
4.52%
Regolith Capital Investments LP
3.03%
Other
43.79%
Shareholder Types
Shareholders
Proportion
Individual Investor
48.37%
Corporation
12.51%
Investment Advisor/Hedge Fund
0.52%
Hedge Fund
0.27%
Investment Advisor
0.24%
Research Firm
0.16%
Venture Capital
0.04%
Other
37.90%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
52
4.57M
62.09%
+1.56M
2025Q1
56
2.92M
80.53%
+838.33K
2024Q4
54
33.02M
64.27%
+30.12M
2024Q3
67
2.84M
52.46%
-257.40K
2024Q2
83
2.52M
46.53%
-624.19K
2024Q1
121
2.54M
46.88%
-584.16K
2023Q4
126
2.36M
43.79%
-543.57K
2023Q3
142
2.77M
52.76%
-391.46K
2023Q2
146
2.77M
53.56%
-376.86K
2023Q1
150
2.98M
67.03%
+101.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cherington (Charles)
2.78M
37.73%
+1.42M
+104.20%
Jun 09, 2025
Freebird Partners LP
414.10K
5.63%
--
--
Apr 14, 2025
Halpern (John D)
390.45K
5.3%
--
--
Apr 14, 2025
Denny George P Iii
332.71K
4.52%
+3.36K
+1.02%
Apr 14, 2025
Regolith Capital Investments LP
222.88K
3.03%
--
--
Apr 14, 2025
IAF, LLC
217.03K
2.95%
--
--
Apr 14, 2025
Purchase Capital LLC
66.67K
0.91%
+66.67K
--
Dec 31, 2024
Singer (Nicholas Jason)
54.00K
0.73%
+54.00K
--
Dec 31, 2024
Geode Capital Management, L.L.C.
19.54K
0.27%
+2.39K
+13.93%
Mar 31, 2025
Corient Private Wealth LLC
17.52K
0.24%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Date
Type
Ratio
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Oct 12, 2022
Merger
20<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
Mar 24, 2021
Merger
2<1
